BIOMARIN PHARMACEUTICAL INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83 USD | +2.87% |
|
+8.74% | -13.83% |
| 07:41pm | Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion | DJ |
| 12:39pm | KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24 | MT |
ETFs positioned on BioMarin Pharmaceutical Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.45% | 1 M€ | +0.84% | - | |
| 1.79% | 0 M€ | 0.00% | - | |
| 1.59% | 0 M€ | 0.00% | - | |
| 0.83% | 15 M€ | -4.01% | ||
| 0.77% | 4 M€ | +20.15% | ||
| 0.47% | 252 M€ | +8.06% | ||
| 0.44% | 21 M€ | +7.83% | - | |
| 0.20% | 9 M€ | +15.45% | - | |
| 0.19% | 9 M€ | -.--% | - | |
| 0.09% | 825 M€ | +11.11% | ||
| 0.09% | 9 M€ | +7.98% | - | |
| 0.07% | 276 M€ | +11.40% | - | |
| 0.07% | 2,334 M€ | +16.63% | ||
| 0.06% | 9 M€ | +9.52% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.05% | 7 M€ | +0.11% | - | |
| 0.05% | 261 M€ | -.--% | - | |
| 0.05% | 200 M€ | +11.72% | - | |
| 0.05% | 488 M€ | +14.78% | ||
| 0.04% | 26 M€ | +16.85% | - | |
| 0.04% | 35 M€ | +14.31% | - | |
| 0.04% | 2,567 M€ | +15.32% | - | |
| 0.03% | 205 M€ | -.--% | ||
| 0.03% | 288 M€ | +21.94% | ||
| 0.03% | 206 M€ | -.--% | ||
| 0.03% | 607 M€ | +0.05% | - |
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
80.69
USD
Average target price
108.1
USD
Spread / Average Target
+33.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.83% | 15.32B | |
| +0.82% | 91.94B | |
| -3.16% | 38.74B | |
| +64.83% | 26.66B | |
| -5.39% | 13.3B | |
| -11.38% | 11.65B | |
| +156.85% | 10.37B | |
| -49.84% | 10.12B | |
| +2.32% | 9.06B | |
| -16.26% | 7.46B |
- Stock Market
- Equities
- BMRN Stock
- Funds and ETFs BioMarin Pharmaceutical Inc.
